(Orange County Business Journal, September 28, 2015) – Irvine-based PhageTech Inc. said it closed on $2.4 million in Series A financing to complete development and U.S. Food and Drug Administration approval for disease sensor technology and to commercialize a blood and urine test for bladder cancer.
Funding was co-led by Mark IV Capital Inc. in Newport Beach and Black River Investments LLC in Pebble Beach.